Piramal Pharma Limited (NSE:PPLPHARMA)
India · Delayed Price · Currency is INR 184.15
+4.30 (2.39%)
May 11, 2026, 3:30 PM IST
Piramal Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | -3,259 | 911.3 | 178.2 | -1,865 | 3,760 |
Depreciation & Amortization | 8,312 | 7,796 | 7,170 | 6,568 | 5,762 |
Other Amortization | - | 367.9 | 235.5 | 199 | 99.7 |
Loss (Gain) From Sale of Assets | -22.3 | -14.4 | 4.6 | 4.8 | 5.4 |
Asset Writedown & Restructuring Costs | 62 | - | - | - | - |
Loss (Gain) From Sale of Investments | -191.6 | -90.5 | 4.8 | -25.6 | -231.3 |
Stock-Based Compensation | 417.2 | 480 | 274.7 | - | - |
Provision & Write-off of Bad Debts | 308.6 | 269.6 | 319 | 420.5 | 74.4 |
Other Operating Activities | 5,633 | 4,081 | 4,202 | 2,558 | 1,117 |
Change in Accounts Receivable | 2,172 | -2,335 | -3,914 | 892.6 | -1,852 |
Change in Inventory | -7,981 | -1,971 | -5,318 | -1,726 | -1,756 |
Change in Accounts Payable | 7,780 | 182.4 | 4,043 | -2,717 | 791.2 |
Change in Other Net Operating Assets | 3,294 | -753.9 | 2,845 | 529.5 | -106 |
Operating Cash Flow | 16,526 | 8,923 | 10,045 | 4,839 | 7,664 |
Operating Cash Flow Growth | 85.21% | -11.17% | 107.60% | -36.86% | 38.94% |
Capital Expenditures | -8,900 | -6,644 | -7,120 | -9,648 | -8,895 |
Sale of Property, Plant & Equipment | 134.4 | 52.5 | 16 | 196.9 | 324.2 |
Cash Acquisitions | - | - | -63.3 | -733.1 | -8,047 |
Investment in Securities | 72.3 | 1,191 | 2,586 | -3,958 | -2,326 |
Other Investing Activities | 433.2 | 626.1 | 241.3 | 754.1 | 822.7 |
Investing Cash Flow | -8,260 | -4,775 | -4,340 | -13,388 | -18,121 |
Short-Term Debt Issued | 9,848 | 8,586 | - | 18,219 | 22,536 |
Long-Term Debt Issued | 9,026 | 2,546 | 2,401 | 25,628 | - |
Total Debt Issued | 18,874 | 11,132 | 2,401 | 43,847 | 22,536 |
Short-Term Debt Repaid | - | - | -3,504 | -14,647 | -9,965 |
Long-Term Debt Repaid | -16,044 | -10,922 | -8,784 | -17,570 | -2,684 |
Total Debt Repaid | -16,044 | -10,922 | -12,288 | -32,218 | -12,649 |
Net Debt Issued (Repaid) | 2,830 | 210.1 | -9,886 | 11,629 | 9,887 |
Issuance of Common Stock | 28.1 | - | 10,500 | - | - |
Common Dividends Paid | -185.5 | -144.7 | - | -670 | -500 |
Other Financing Activities | -3,062 | -4,474 | -4,837 | -2,781 | -1,445 |
Financing Cash Flow | -389.8 | -4,408 | -4,224 | 8,178 | 7,942 |
Foreign Exchange Rate Adjustments | 63.5 | -108.8 | 177.9 | 51.5 | -20.4 |
Miscellaneous Cash Flow Adjustments | 0.1 | - | - | - | 767.4 |
Net Cash Flow | 7,939 | -368.7 | 1,660 | -319.5 | -1,768 |
Free Cash Flow | 7,626 | 2,279 | 2,925 | -4,809 | -1,231 |
Free Cash Flow Growth | 234.58% | -22.08% | - | - | - |
Free Cash Flow Margin | 8.60% | 2.49% | 3.58% | -6.79% | -1.83% |
Free Cash Flow Per Share | 5.75 | 1.71 | 2.28 | -4.04 | -1.04 |
Cash Interest Paid | 3,062 | 4,474 | 4,696 | 2,781 | 1,445 |
Cash Income Tax Paid | 2,102 | - | - | 1,890 | 1,694 |
Levered Free Cash Flow | 6,747 | -1,437 | -1,021 | -8,740 | -8,823 |
Unlevered Free Cash Flow | 8,877 | 1,175 | 1,773 | -6,630 | -7,643 |
Change in Working Capital | 5,266 | -4,877 | -2,343 | -3,021 | -2,923 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.